ATOPIC DERMATITIS

This study tracks 183 adults with moderate-to-severe atopic dermatitis (eczema) who take abrocitinib tablets daily for up to 24 months. Researchers want to see how well the drug clears skin and eases symptoms in real-life settings, not just in controlled trials. Participants can …

This study looks at the long-term safety and effectiveness of APG777 in people with moderate-to-severe eczema who have already been treated with the drug in a previous study. About 350 adults will receive APG777 for an extended period and be monitored for side effects and skin im…

This program provides early access to upadacitinib, an investigational drug, for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis. It is for those who have no other suitable treatment options and cannot join a clinical trial. A doc…

This study tests an oral medication called ICP-332 for adults with moderate to severe atopic dermatitis (eczema) who haven't responded well to standard creams. About 552 participants will receive either the drug or a placebo to see if it significantly reduces eczema severity and …

This study tests a new medicine called IBI3002 for people with moderate to severe atopic dermatitis (eczema). About 120 adults will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching. The main goal is to measure improvement in eczema se…

This study tests if a drug called tralokinumab, given as a shot plus steroid cream, is safe and works for children (2 to under 12 years) and infants (6 months to under 2 years) with moderate-to-severe eczema. Children are randomly assigned to get the drug or a placebo for 16 week…

This study tests whether baricitinib, a drug already approved for other immune conditions, is safe for people with Job syndrome who also have lupus-like disease or eczema. About 20 people aged 12 and older will take the pill daily for 6 months. Researchers will monitor side effec…

This study tests two approved drugs, upadacitinib and dupilumab, in children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. About 675 kids worldwide will take either a daily pill or an injection every few weeks. The goal is to see which works better …

This study looks at how well the oral medication abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried up to two biologic drugs without success or had side effects. About 150 participants aged 12 and older will be followed in real-…

This study tests upadacitinib, an approved eczema pill, in adults with moderate to severe eczema who didn't get enough relief from dupilumab. About 200 participants will receive upadacitinib or continue dupilumab for 32 weeks, with the option to adjust doses. The goal is to see i…

This study tests new investigational drugs for people with moderate to severe atopic dermatitis (eczema). About 224 adults will receive either the study drug or a placebo. The main goal is to see if the drug reduces eczema severity, measured by a standard skin score, after 16 wee…

This study tests whether ZL-82 tablets can safely reduce eczema symptoms in adults with moderate to severe atopic dermatitis. About 111 participants will take either ZL-82 or a placebo daily for 16 weeks, with regular checkups to track skin improvement and side effects. The goal …

This study tests an experimental drug called FB825 in 90 adults with moderate-to-severe atopic dermatitis (eczema). Participants receive either FB825 or a placebo via injection under the skin. The goal is to see if the drug reduces eczema severity and itching, and to check its sa…

This study tests a cream made with a harmless bacteria (Staphylococcus hominis A9) to see if it can safely control eczema in adults and teens. Participants apply the cream for 14 weeks, starting with a short course of steroid cream. The goal is to see if the bacteria cream can de…

This study tests an oral medication called roflumilast in 36 people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). Participants take a daily pill for 12 weeks to see if it reduces skin redness, itching, and sleep problems. The goal is to check if the drug i…

This study looks at whether children aged 1 to 17 with well-controlled eczema can safely take less dupilumab or stop it altogether. About 30 kids who have been on the drug for at least a year will be randomly assigned to reduce their dose or stop. The goal is to see if they can m…

This study tests the long-term safety and effectiveness of a daily liquid medicine called abrocitinib for children aged 2 and older with moderate-to-severe eczema. About 500 kids will take the medicine for up to 24 months, with or without topical creams. The goal is to see if the…

This study looks at whether adults with controlled atopic eczema can safely extend the time between dupilumab injections from every 2 weeks to every 3 or 4 weeks. About 216 participants will be randomly assigned to one of three dosing schedules. Researchers will compare eczema se…

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema). It is for 120 adults who already took part in earlier afimkibart studies. Researchers will track side effects and measure how well the drug controls eczem…

This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area. About 200 participants will receive either the drug or a placebo for 16 w…

This study is tracking 1,000 teens and adults with moderate-to-severe atopic dermatitis (eczema) who are starting nemolizumab as part of their normal medical care. Researchers want to see how well the drug controls skin symptoms and itching after 6 months, using both doctor ratin…

This study tests a new medication called IMG-007 in adults with moderate-to-severe eczema (atopic dermatitis). About 220 participants will receive either IMG-007 or a placebo to see if it safely reduces skin symptoms like redness and itching. The main goal is to measure improveme…

This study looks at how well upadacitinib, an approved eczema drug, works in real-world settings for about 1,000 teens and adults with moderate to severe atopic dermatitis in China. Participants take the drug as prescribed by their doctor and are followed for 12 months. The goal …

This study tests two experimental medicines (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams. About 340 participants will receive the drugs or a placebo as injections over several months. The goal is…

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or patchy hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin and scalp problems. The goal is to manage symptoms, not cure the…

This study tests a new medication, galvokimig, in 160 adults with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure how many people achieve at …

This study tests an experimental drug called IBI356 in 403 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it reduces skin redness, itching, and rash. The goal is to control the disease, not cure it, and resul…

This study tests whether a spray made from ground cardamom and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms. About 120 people aged 2 and older with eczema will use the spray at home 2-3 times a week for 14 weeks. The goal is to see if it reduces rash a…

This study tests a new skin barrier cream against plain petrolatum (Vaseline) in 26 adults with mild skin conditions like eczema, psoriasis, or dry skin. Participants apply the cream twice daily for 28 days. Researchers measure skin hydration, redness, and itch to see if the new …

This study tests a cream called tapinarof for children aged 3 to 23 months with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin within 8 weeks. About 180 children will take part, and the cream will be compared to a cream without medicine.…

This early-stage study is testing a new drug called BxC-I17e in 45 adults with moderate to severe eczema (atopic dermatitis). The main goal is to see if the drug is safe and tolerable when given as a shot under the skin. Participants will receive either the drug or a placebo, and…

This study tests an investigational drug called SM17, given as a shot under the skin, for adults with moderate-to-severe atopic dermatitis (eczema). About 200 participants will receive either SM17 or a placebo to see if it safely reduces eczema severity and itching. The goal is t…

This study tests a cream called ruxolitinib for children and teens aged 6 to 17 with moderate eczema. The goal is to see if it safely reduces skin redness, itching, and rash. About 240 participants will use either the cream or a placebo for a few weeks.

This early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to check safety and how the body handles the drug. About 198 people will take part, and some will receive a placebo. This is…

This study tests a new medicine called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 people will receive either the drug or a placebo to see if it reduces skin redness, swelling, and itching. The main goal is to measure improvement in eczem…

This study follows 184 adults with moderate-to-severe atopic dermatitis (eczema) who also have anxiety or depression. All participants are already starting dupilumab as part of their regular care. Researchers will track changes in anxiety, depression, and quality of life over 6 m…

This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate-to-severe eczema (atopic dermatitis). The main goals are to check safety and how well the body handles the drug. In the second part, researchers will also see if it improves s…

This study is testing a cream (RV4421B-EV0407) for mild to moderate atopic dermatitis (eczema) in people aged 3 months and older, including those with dark skin. The cream is already sold in some countries. Researchers want to see how safe and effective it is when used alone or w…

This study tests a new daily pill, soquelitinib, in 200 adults with moderate to severe atopic dermatitis (eczema). Participants take the drug or a placebo for 12 weeks. Doctors track skin improvements and side effects to see if the drug is safe and works better than a dummy pill.

This study looks at whether dupilumab, a medication for moderate to severe eczema, can improve sleep and reduce itching in children aged 6 to 17. Researchers will track sleep quality and itchiness over 12 weeks. The goal is to see if treating the skin condition also helps kids re…

This study tests an experimental ointment called GX-03 in adults with moderate to severe eczema. About 110 participants will apply either GX-03 or a placebo cream daily for 8 weeks. Researchers will check if the treatment clears skin, reduces itch, and improves quality of life.

This study tests a new drug called BGB-45035 for the first time in humans. It will check safety and how the body processes the drug in healthy volunteers, then test it in people with autoimmune skin diseases like eczema and prurigo nodularis. The goal is to see if the drug is saf…

This early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug. About 63 people will take part, and some will receive a placebo. This is …

This early-stage study tests a new drug called PF-07832837 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs that it might im…

This study tests a drug called lebrikizumab in 200 adults and teens with moderate eczema who have severe itching. The goal is to see if the drug can significantly reduce itch and clear skin patches over 6 months of treatment. Participants will receive the drug alone, without othe…

This study tests whether a daily probiotic drop (BioAmicus Complete) can ease tummy issues like colic, constipation, and diarrhea, as well as skin symptoms of food allergy (eczema) in infants. About 140 babies will receive either the probiotic or a placebo for 25 days. The goal i…

This study looks at whether eating a diet low in unhealthy fats and rich in whole grains, fruits, and vegetables can reduce the severity of eczema (atopic dermatitis) in young adults. Researchers will track changes in skin symptoms and barrier function over two months. The goal i…

This study is testing a new laser (PALLAS) to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 adults will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition and i…

This study follows 1,000 people with eczema and related allergies (like asthma or food allergies) to learn why some get better and others don't. Researchers collect health data and samples over time to find patterns and possible biomarkers. No new treatments are given—participant…

This study looks at whether people with a certain gene change (IL-4Ra R576) have more severe eczema. Researchers will measure skin symptoms, immune markers, and skin bacteria in 111 participants aged 6 to 65. No new treatment is given—the goal is to better understand why some peo…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored for current and future research to better understand these conditions. Participants must be 18 or older and have a confirmed dia…

This study aims to find out how often adults with atopic dermatitis (eczema) have eyelid involvement, which can greatly affect quality of life. Researchers will track 550 patients in France, describing the type of eyelid eczema and looking for related factors like allergies or ot…

This study looks for shared genetic and chemical clues between eczema (atopic dermatitis) and food allergies. Researchers will collect blood and skin samples from 200 people, including those with food allergies, eczema, or neither. The goal is to create a molecular map that could…

This study aims to find better ways to help people with atopic dermatitis (eczema) use their topical medication as prescribed. About 30 participants will be split into groups: one gets standard care, another gets a hands-on demonstration, and a third uses a mobile app. Researcher…

This study aims to learn more about what causes food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will follow up to 1,800 people (ages 2-99) and their relatives for up to 12 years, collecting blood, skin, and genetic samples. The goal is …

This study creates a database of 400 children and young adults with eczema who are using or will start systemic (whole-body) treatments. Researchers will track how well these treatments work by reviewing medical records and patient surveys. The goal is to make it easier to recrui…

This study is creating a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, and severe asthma. Researchers will track disease activity, quality of life, and treatment responses over time. The goal is to find new markers …

This study will follow 600 French adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already taking systemic medications. Researchers will observe which treatments doctors prescribe, how long patients stay on them, and how well they follow the treat…

This study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their normal care. Researchers will track symptoms, quality of life, and disease control over 2 years using questionnaires and checkups. The goal is to understand ho…

This study looks at how the eczema drug dupilumab affects people of different ethnic backgrounds. Researchers want to understand why Asian and African American people get eczema more often and if their bodies respond differently to treatment. The study will involve 30 adults with…

This study looks at over 5,600 pregnant women with eczema to see if using ruxolitinib cream affects the baby's health compared to using standard steroid creams. Researchers will track birth defects, birth weight, and pregnancy outcomes using insurance claims data. The goal is to …

This study watches pregnant women with eczema who take the medicine CIBINQO (abrocitinib) and compares them to pregnant women with eczema who do not take it. The goal is to see if the medicine affects the baby's health at birth or during the first year of life. About 400 women wi…

This study is a registry that will follow about 1,500 teenagers (ages 12-15) with moderate-to-severe atopic dermatitis (eczema) to see how well their treatments work and if there are any side effects. Participants are already starting or have recently started a new medication for…

This study looks at the tiny organisms living on human skin, like bacteria and fungi, to understand how they affect health and eczema. Researchers will compare healthy volunteers and people with moderate to severe eczema, aged 2 to 40. Participants provide skin swabs, scrapings, …

This study follows about 958 pregnant women with mild to moderate eczema to see if using ruxolitinib cream affects pregnancy or baby health. Researchers compare those who used the cream with those who did not, focusing on birth defects and other outcomes. The goal is to gather sa…

This early-stage study tests a new drug called CKD-706, which is similar to the approved eczema treatment Dupixent. About 519 healthy adults will receive a single dose of either CKD-706, the US version of Dupixent, or the European version. The goal is to compare how the body proc…

This study collects skin samples from people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. The goal is to analyze genes and other markers to better understand what causes these inflammatory skin diseases. No treatment is given; it is purely for …

This study will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments are used, how well they work, and how the disease changes over 5 years. The goal is to better understand patien…

This study aims to understand how the immune system and skin healing are connected. Researchers will study people with primary immune deficiency, eczema, or psoriasis, as well as healthy volunteers. Participants will provide blood and skin samples to help identify differences in …

This study aims to better understand chronic hand eczema and atopic dermatitis by using noninvasive techniques like skin tape strips and imaging. Researchers will compare skin features and molecular patterns between people with these conditions and healthy volunteers. The goal is…